Inhaled long-acting muscarinic antagonists in chronic obstructive pulmonary disease

Future Medicinal Chemistry

Volumn 3, Issue 13, 2011, Pages 1623-1634

  Busch Petersen, Jakob ^a   Lainé, Dramane I ^b  

^a GLAXOSMITHKLINE   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; ATROPINE; AZD 8683; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHF 5407; CHOLINERGIC RECEPTOR BLOCKING AGENT; DAROTROPIUM BROMIDE; DEXPIRRONIUM; GLYCOPYRRONIUM BROMIDE; GSK 573719; INDACATEROL; IPRATROPIUM BROMIDE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXITROPIUM BROMIDE; PF 3635659; PT 001; SCOPOLAMINE; TD 4208; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; VILANTEROL;

ANTICHOLINERGIC EFFECT; BRONCHITIS; BRONCHOSPASM; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SOLUBILITY; EMPHYSEMA; HUMAN; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; XEROSTOMIA;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; HUMANS; MOLECULAR WEIGHT; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 80053208252     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.127     Document Type: Review

References (67)

1. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 50, 279-290 (1998).
2. Eglen RM. Muscarinic receptor subtype pharmacology and physiology. Prog. Med. Chem. 43, 105-136 (2005). (Pubitemid 40605496)
3. Caulfield MP. Muscarinic receptors - characterization, coupling and function. Pharmacol. Ther. 58, 319-359 (1993).
4. Lee AM, Jacoby DB, Fryer AD. Selective muscarinic receptor antagonists for airway diseases. Cur. Opin. Pharmacol. 1, 223-229 (2001). (Pubitemid 33585966)
5. Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2, 297-304 (2005). (Pubitemid 41566939)
6. Barnes PJ. New muscarinic receptor subtypes: implications for lung disease. Thorax 44, 161-167 (1989). (Pubitemid 19087144)
7. Gater PJ, Alabastar VJ, Piper I. A Study of the muscarinic receptor subtype mediating secretion in the cat trachea in vitro. Pul. Pharmacol. 2, 87-92 (1989). (Pubitemid 19182411)
8. Wessler I, Libinger H, Bittinger F et al. The non-neuronal cholinergic system in humans: expression, function and pathophysiology. Life Sci. 72, 2055-2061 (2003). (Pubitemid 36298947)
9. Fernandes LB, Fryer AD, Hirshman CA. M2 muscarinic receptors inhibit isoproterenol-induced relaxation of canine airway smooth muscle. J. Pharmacol. Exp. Ther 262, 119-126, (1992).
10. Faulkner D, Fryer AD, MacLagan J. Postganglionic muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea pig. Br. J. Pharmacol. 88, 181-187 (1986). (Pubitemid 16020791)
11. Lammers JJ, Minette P, McCusker M, Barnes PJ. The role of pirenzepine-sensitive (m1) muscarinic receptors in vagally mediated bronchoconstriction in humans. Am. Rev. Respir. Dis. 139, 446-449 (1989). (Pubitemid 19057423)
12. Jartti T. Asthma, asthma medication and autonomic nervous system dysfunction. Clin. Phys. 21(2), 260-269 (2001).
13. Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir. Res. 7(1), 73-87 (2006).
14. Fryer AD, Adamko DJ, Yost BL, Jacoby DB. Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung. Life Sci. 64, 449-455 (1999). (Pubitemid 29066692)
15. Barnes P. Chronic obstructive pulmonary disease. N. Engl. J. Med. 343, 269-280 (2000). (Pubitemid 30490396)
16. Rabe K, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 176, 532-555 (2007). (Pubitemid 47403272)
17. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370, 760-773 (2007).
18. Donalson GC, Wedzicha JA. COPD exacerbations 1: epidemiology. Thorax 61, 164-168 (2006).
19. Sapey E, Stockley RA. COPD exacerbations 2: aetiology. Thorax 61, 250-258 (2006).
20. Mui T, Man P, Sin D. Developments in drugs for the treatment of chronic pulmonary disease. Expert Rev. Clin. Immunol. 4, 365-377 (2008). (Pubitemid 351903274)
21. Murray C, Lopez A. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 349, 1498-1504 (1997). (Pubitemid 27216360)
22. Calverley P. COPD: What is the unmet need? Br. J. Pharmacol. 155, 487-493 (2008).
23. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Immunol. Rev. 8, 183-192 (2008). (Pubitemid 351323287)
24. Gross N. Ipratropium bromide. New Eng. J. Med. 319 (8), 486-494 (1988).
25. Gross JN. Anticholinergic agents in asthma and COPD. Eur. J. Pharm. 533, 36-39 (2006).
26. Joos GF. Potential for long-acting muscrinic antagonists in chronic obstructive pulmonary disease. Exp. Opin. Invenstig. Drugs 19, 257-264 (2010).
27. Barnes P. Tiotropium bromide. Drugs 62, 1195-1203 (2002).
28. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur. Respir. J. 34, 1-13 (2009).
29. Disse B, Reichl R, Speck G, Traunecker W, Rominger KL, Hammer R. BA679BR, a novel long-acting anticholinergic bronchodilator. Life Sci. 52, 537-544 (1993).
30. Sheppard D, Epstein J, Holtzman MJ, Nadel JA, Boushey HA Effect of route of atropine delivery on bronchospasm from cold airand methacholine. J. Appl. Physiol. 54, 130-133 (1983). (Pubitemid 13110561)
31. Takahashi T, Belvisi MG, Patel H et al. Effect of Ba679BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am. J. Respir. Crit. Care Med. 150, 164-1645 (1994).
32. Hansel T, Barnes P. Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today 38 (9), 585-600 (2002). (Pubitemid 35190691)
33. Barnes P. Tiotropium bromide. Exp. Opin. Invest. Drugs 10(4), 733-740 (2001). (Pubitemid 32288190)
34. ZuWallack A, ZuWallack R. Tiotropium bromide, a new once-daily inhaled anticholinergic bronchodilator for chronic obstructive pulmonary disease. Exp. Opin. Pharmacother. 5(8), 1827-1835 (2004). (Pubitemid 39117725)
35. Lipson D. Tiotropium bromide. Int. J. COPD 1(2), 107-114 (2006).
36. Leusch A, Eichhorn B, Muller G, Romiger K. Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. Drug. Dispos. 22, 199-212 (2001).
37. Santus P, Di Marco. Safety and pharmacology of tiotropium bromide. Exp. Opin. Drug Saf. 8(3), 387-395 (2009).
38. Franko B, Alphin R, Ward J, Lunsford C. Pharmacodynamic evaluation of glycopyrrolate in animals. Ann. NY Acad. Sci. 99, 131-149 (1962).
39. Walker 4th F, Kaiser D, Kowal M, Suratt P. Prolonged effect of inhaled glycopyrrolate in asthma. Chest 91, 49-51 (1987). (Pubitemid 17215791)
40. Schroeckenstein D, Bush R, Chervinsky P, Busse W. Twelve-hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate. J. Allergy Clin. Immunol. 82, 115-119 (1988).
41. Tzelepis G, Komanapolli, Tyler D, Vega D, Fulambarker A. Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease. Eur. Respir. J. 9, 100-103 (1996). (Pubitemid 26037532)
42. Haddad E-B, Patel H, Keeling J, Yacoub M, Barnes P, Belvisi M. Pharmacological characterization of the muscarinic receptor, glycopyrrolate, in human and guinea pig airways. Br. J. Pharmacol. 127, 413-420 (1999). (Pubitemid 29245679)
43. Villetti G, Bergamaschi M, Bassani F et al. Pharmaocolical assessement of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea pig and human airways. Br. J. Pharmacol. 148, 291-298 (2006). (Pubitemid 43801176)
44. Hansel T, Neighbour H, Erin EM et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilation in patients with asthma. Chest 128, 1974-1979 (2005). (Pubitemid 41507530)
45. Verkindre C, Fukuchi Y, Flemale A, Takeda A, Overend T, Prasad N et al. Sustained 24 h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir. Med. 104, 1482-1489 (2010).
46. Vogelmeier C, Verkindre C, Cheung D et al. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm. Pharmacol. Ther. 23, 438-444 (2010).
47. Fogarty C, Hattersley H, Di Scala L, Drollmann A. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir. Med. 105, 337-342 (2011).
48. Prat M, Fernandez D, Buil AM et al. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxyl(di-2-thienyl)acetyl] oxy}-1-(3-phenoxypropyl)-1- azoniabicyclo[2.2.2]octane bromide (aclidinium bromide).J. Med. Chem. 52, 5076-5092 (2009).
49. Hoffstetter S, Leong FC. Solifenacin succinate for the treatment of overactive bladder. Expert Opin. Drug Metab. Toxicol. 5(3), 345-350 (2009).
50. 3 antagonist for the treatement od COPD. Curr. Opin. Inves. Drugs 10 (5), 482-490 (2009).
51. Lock R, Collingwood S, Ratcliffe A. Emerging therapies for respiratory diseases. Drug News Perspect. 20 (9), 593-600 (2007). (Pubitemid 351480212)
52. Gavalda A, Miralpeix M, Ramos I et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile J. Pharm. Exp. Ther. 331(2), 740-751 (2009).
53. Casarosa P, Bouysson T, Germeyer S et al. Preclinical evaluation of long acting muscarinic antagonists (LAMAs): comparison of tiotropium and investigational drugs. J. Pharm. Exp. Ther. 330(2), 660-668 (2009).
54. Sentellas S, Ramos I, Alberti J et al. Aclidinium bromide, a new, long acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur. J Pharm. Sci. 39(5), 283-290 (2010).
55. Alberti J, Martinet A, Sentellas S, Salva M. Indentification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide Drug Metab. Disp. 38(7), 1202-1210 (2010).
56. Vestbo J, Vogelmeier, C, Creemers J, Falques M, Ribera A, Garcia Gil E. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. J. Chron. Obstruct. Pulmon. Dis. 7, 331-336 (2010).
57. Laine DI, Wan Z, Yan H et al. Design, synthesis and SAR of tropane muscarinic acetylcholine receptor antagonists. J. Med. Chem. 52, 5241-5252 (2009).
58. Laine DI, Xie H, Buffet N et al. Discovery of novel 8-azoniabicyclo[3.2. 1]octane carbamates as muscarinic acetylcholine receptor antagonists. Bioorg. Med. Chem. Lett. 17, 6066-6069 (2007). (Pubitemid 47552852)
59. Laine DI, McCleland B, Thomas S et al. Discovery of novel 1-azoniabicyclo[2.2.2] octane muscarinic acetylcholine receptor antagonists. J. Med. Chem. 52 (8), 2493-2505 (2009).
60. Jin J, Wang Y, Shi D, Wang F, Davis R, Jin Q et al. Discovery of novel and long acting muscarinic acetylcholine receptor antagonists. J. Med. Chem. 51, 4866-4869 (2008).
61. Jin J, Budzik B, Wang Y et al. Discovery of biphenyl piperazines as novel and long acting muscarinic acetylcholine receptor antagonists. J. Med. Chem. 51, 5915-5918 (2008).
62. 3 receptor antagonist. J. Pharmacol. Exp. Ther. 335, 622-635 (2010).
63. 3 antagonists. Bioorg. Med. Chem. Lett. 20, 7458-7461 (2010).
64. Gupta S, Malhotra S, Sinha S et al. Pharmacodynamic and pharmacokinetic profile of RBx 343E48FO: a novel, long acting muscarinic receptor antagonist. Eur. J. Pharm. 658, 219-228 (2011).
65. Ritchie TR, Luscombe CN, Macdonald SJF. Analysis of the calculated physicochemical properties of respiratory drugs: can we design for inhaled drugs yet? J. Chem. Inf. Model. 49, 1025-1032 (2009).
66. Valko KL, Nunhuck SB, Hill AP Estimating the unbound volume and distribution and tissue binding by in vitro HPLC-based human serum albumin and immobilized artificial membrane-binding measurements J. Pharm. Sci. 100, 849-862 (2011).
67. Nakamura T, Nakanishi T, Haruta T, Shirasaka Y, Keogh JP, Tamai I. Transporter of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnetine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol. Pharm. 7, 187-195 (2010).